Mantle Cell Lymphoma Younger Trial Shows Survival Improvement in Long-Term Follow Up Study
Researchers sought to evaluate first-line treatment of patients with advanced-stage MCL who were younger than 66 years of age.
All articles by Lauren Dembeck, PhD
Novel Risk Prediction Tool May Identify Patients With Multiple Myeloma at a High Risk of Venous Thromboembolism
Researchers sought to determine whether the PRISM score would be able to identify patients with multiple myeloma at a high risk of VTE.
Associations of Mutations in Spliceosome Genes With Ring Sideroblasts Verified in Myelodysplastic Syndromes
Researchers sought to verify the association of mutations in the splicing pathway gene SF3B1 with low bone marrow blast counts and increased ring sideroblasts in MDS.
Less May Be More When Treating Newly Diagnosed AML
Neither a higher dose of daunorubicin nor a second induction cycle improved outcomes in fit patients with newly diagnosed acute myeloid leukemia.
Adding Ibrutinib to Induction and Maintenance Improves FFS in Mantle Cell Lymphoma
Adding ibrutinib to induction and maintenance after transplant improves failure-free survival in patients with mantle cell lymphoma, results of the TRIANGLE study suggest.
Monoclonal Antibody Shows Promise for Treating MPNs in Preclinical Study
Preclinical research suggests that a monoclonal antibody may be effective for treating CALR-mutant myeloproliferative neoplasms.
Salvage Chemotherapy Before Allo-HSCT Does Not Improve Outcomes in Rel/Ref AML
Salvage chemotherapy before allogeneic transplant does not improve outcomes in relapsed/refractory acute myeloid leukemia, a phase 3 study suggests.
Quadruplet Produces Deep Responses in High-Risk, Newly Diagnosed Multiple Myeloma
Isatuximab plus carfilzomib, lenalidomide, and dexamethasone can produce deep responses in patients with high-risk, newly diagnosed multiple myeloma, a phase 2 trial suggests.
Teclistamab Plus Daratumumab and Lenalidomide Shows Promise in Rel/Ref Multiple Myeloma
Teclistamab plus daratumumab and lenalidomide produced deep and durable responses in patients with relapsed or refractory multiple myeloma.
Routine Use of Axicabtagene Ciloleucel Could Be Cost Effective in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Researchers sought to determine whether the use of second-line CAR-T therapy could be cost effective in DLBCL.
- Loading...
Loading...
Next post in Lymphoma
Loading... 
Loading...